PRISCILLA SALVADOR: Open Payments
NPI 1982342812 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,376 in 59 payments from 12 companies in 2025. Trend: 2023 $710 · 2024 $1,865 · 2025 $1,376
Food & beverage: $1,376
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $625 |
| AKEBIA THERAPEUTICS INC | 9 | $192 |
| Aurinia Pharma U.S., Inc. | 7 | $136 |
| Novo Nordisk Inc | 4 | $92 |
| Calliditas Therapeutics US Inc. | 3 | $65 |
| Ardelyx, Inc. | 3 | $63 |
| Vifor Pharma, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Fresenius USA Marketing, Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $23 |
Products named: FARXIGA, Vafseo, LUPKYNIS, AIRSUPRA, TARPEYO, IBSRELA, Veltassa, BREZTRI.
Industry payments across CA — which companies pay providers there.
